Enanta Pharmaceuticals Inc expected to post a loss of $1.35 a share - Earnings Preview

Enanta Pharmaceuticals

07/02/2025 21:54

* Enanta Pharmaceuticals Inc  ENTA.OQ   ENTA.O  is expected
to show a fall in quarterly revenue when it reports  results on
February 10 (estimated) for the period ending December 31 2024
    * The Watertown Massachusetts-based  company is expected to
report
a 4.2% decrease in revenue to $17.249 million from $18 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Enanta Pharmaceuticals
Inc is
for a loss of $1.35 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $18.00​, above​ its last closing price
of $4.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -1.10       -1.16      -1.36     Missed  -17.2
 Jun. 30 2024  -1.40       -1.45      -1.07     Beat    26.2
 Mar. 31 2024  -1.39       -1.30      -1.47     Missed  -13.2​
 Dec. 31 2023  -1.19       -1.19      -1.58     Missed  -32.3
 ​​Sep.        -2.17       -2.15      -1.33     Beat    38
 30 2023                                                
 Jun. 30 2023  -2.37       -2.34      -1.86     Beat    20.4​
 Mar. 31 2023  -1.94       -1.98      -1.79     Beat    9.6
 Dec. 31 2022  -1.59       -1.59      -1.39     Beat    12.9
 This summary was machine generated February 7 at 21:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)